Development Translational Medicine in hepatitis C vaccine

Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Development Translational Medicine in hepatitis C vaccine
Translational medicine has demonstrated first clinical trial of a hepatitis C vaccine in humans in safe and unprecedented immune responses, according to research. Antibodies are produced in B-cells that go after specific invaders. Hepatitis C virus constantly changes and has multiple genotypes which is challenging for scientists to get B-cells to work effectively in a hepatitis C vaccine.
T-cells are used instead of B-cells to target specific intruders, by this new vaccine provokes the immune system to go after the virus self-defense. Nearly 15-25 % of people who are infected with hepatitis C clear the virus spontaneously, according previous records. Researchers have found that a T-cell response plays a role in the ability of body to do so.
The researchers used chimpanzee viruses as vaccine vectors in the trial. The size and breadth of the immune responses are noted in the healthy volunteers which results as unprecedented in magnitude for a hepatitis C vaccine. Different T-cells are produced targeting different parts of the hepatitis C virus. Research is carried out, if it is able to prevent hepatitis C infection.
  • Share this page
  • Facebook
  • Twitter
  • LinkedIn
  • Google+
  • Pinterest
  • Blogger